BRCA1 and breast cancer: In summary, AGuIX nanoparticles effectively weakened the homologous recombinant repair ability of the breast cancer cells by inhibiting DNA damage response proteins, such as MRN and ATM, and then inhibiting the phosphorylation of the downstream DNA damage repair proteins p53 and BRCA1.